The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century.
| Title: | The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. |
|---|---|
| Authors: | Caini S; Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.; Kusznierz G; National Institute of Respiratory Diseases 'Emilio Coni', Santa Fe, Argentina.; Garate VV; National Institute of Respiratory Diseases 'Emilio Coni', Santa Fe, Argentina.; Wangchuk S; Royal Centre for Disease Control, Department of Public Health, Ministry of Health, Thimphu, Bhutan.; Thapa B; Royal Centre for Disease Control, Department of Public Health, Ministry of Health, Thimphu, Bhutan.; de Paula Júnior FJ; Ministry of Health, Department of Surveillance of Transmissible Diseases, Brasília/DF, Brazil.; Ferreira de Almeida WA; Ministry of Health, Department of Surveillance of Transmissible Diseases, Brasília/DF, Brazil.; Njouom R; Virology Department, Centre Pasteur of Cameroon, Yaoundé, Cameroon.; Fasce RA; Sub-Department of Viral Diseases, Instituto de Salud Pública de Chile, Santiago, Chile.; Bustos P; Sub-Department of Viral Diseases, Instituto de Salud Pública de Chile, Santiago, Chile.; Feng L; Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, P.R. China.; Peng Z; Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, P.R. China.; Araya JL; National Influenza Center, Ministry of Health, San José, Costa Rica.; Bruno A; National Institute of Public Health Research (INSPI), National Reference Centre for Influenza and Other Respiratory Viruses, Guayaquil, Ecuador.; Agricultural University of Ecuador, Guayaquil, Ecuador.; de Mora D; National Institute of Public Health Research (INSPI), National Reference Centre for Influenza and Other Respiratory Viruses, Guayaquil, Ecuador.; Barahona de Gámez MJ; National Influenza Center, Ministry of Health, San Salvador, El Salvador.; Pebody R; Public Health England, London, England, United Kingdom.; Zambon M; Public Health England, London, England, United Kingdom.; Higueros R; National Influenza Center, Ministry of Health, Guatemala City, Guatemala.; Rivera R; National Influenza Center, Ministry of Health, Tegucigalpa, Honduras.; Kosasih H; US Naval Medical Research Unit No.2, Jakarta, Indonesia.; Castrucci MR; National Influenza Center, Department of Infectious Diseases, National Institute of Health, Rome, Italy.; Bella A; Department of Infectious Diseases, National Institute of Health, Rome, Italy.; Kadjo HA; Department of Epidemic Virus, Institut Pasteur, Abidjan, Côte d'Ivoire.; Daouda C; Service of Epidemiological Diseases Surveillance, National Institute of Public Hygiene, Abidjan, Côte d'Ivoire.; Makusheva A; National Center of Expertise, Committee of Public Health Protection, Ministry of Health, Astana, Kazakhstan.; Bessonova O; National Center of Expertise, Committee of Public Health Protection, Ministry of Health, Uralsk City, Kazakhstan.; Chaves SS; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.; Influenza Program, Centers for Disease Control and Prevention, Nairobi, Kenya.; Emukule GO; Influenza Program, Centers for Disease Control and Prevention, Nairobi, Kenya.; Heraud JM; National Influenza Center, Virology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.; Razanajatovo NH; National Influenza Center, Virology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.; Barakat A; National Influenza Center, Institut National d'Hygiène, Ministry of Health, Rabat, Morocco.; El Falaki F; National Influenza Center, Institut National d'Hygiène, Ministry of Health, Rabat, Morocco.; Meijer A; National Institute for Public Health and the Environment, Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, Bilthoven, The Netherlands.; Donker GA; Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands.; Huang QS; Institute of Environmental Science and Research, Weillngton, New Zealand.; Wood T; Institute of Environmental Science and Research, Weillngton, New Zealand.; Balmaseda A; National Influenza Center, Ministry of Health, Managua, Nicaragua.; Palekar R; Pan American Health Organization, Washington, District of Columbia, United States of America.; Arévalo BM; National Influenza Center, IC Gorgas, Panama City, Panama.; Rodrigues AP; Department of epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.; Guiomar R; National Influenza Reference Laboratory, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.; Lee VJM; Public Health Group, Ministry of Health, Singapore, Singapore.; Ang LW; Public Health Group, Ministry of Health, Singapore, Singapore.; Cohen C; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Treurnicht F; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Mironenko A; L.V.Gromashevsky Institute of Epidemiology and Infectious Diseases, National Academy of Medical Science of Ukraine, Department of Respiratory and other Viral Infections, Kyiv, Ukraine.; Holubka O; L.V.Gromashevsky Institute of Epidemiology and Infectious Diseases, National Academy of Medical Science of Ukraine, Department of Respiratory and other Viral Infections, Kyiv, Ukraine.; Bresee J; Influenza Division, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.; Brammer L; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.; Le MTQ; National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.; Hoang PVM; National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.; El Guerche-Séblain C; Global Vaccine Epidemiology and Modeling Department (VEM), Franchise Epidemiologist, Sanofi Pasteur, Lyon, France.; Paget J; Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands. |
| Corporate Authors: | Global Influenza B Study team |
| Source: | PloS one [PLoS One] 2019 Sep 12; Vol. 14 (9), pp. e0222381. Date of Electronic Publication: 2019 Sep 12 (Print Publication: 2019). |
| Publication Type: | Historical Article; Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: San Francisco, CA : Public Library of Science |
| MeSH Terms: | Influenza B virus/*pathogenicity ; Influenza, Human/*epidemiology; Epidemics/history ; Epidemics/statistics & numerical data ; Influenza A Virus, H1N1 Subtype/immunology ; Influenza A virus/immunology ; Influenza B virus/immunology ; Influenza B virus/metabolism ; Influenza Vaccines/immunology ; Influenza, Human/history ; Population Surveillance/methods ; Epidemiological Monitoring ; Female ; History, 21st Century ; Humans ; Male ; Seasons |
| Abstract: | We describe the epidemiological characteristics, pattern of circulation, and geographical distribution of influenza B viruses and its lineages using data from the Global Influenza B Study. We included over 1.8 million influenza cases occurred in thirty-one countries during 2000-2018. We calculated the proportion of cases caused by influenza B and its lineages; determined the timing of influenza A and B epidemics; compared the age distribution of B/Victoria and B/Yamagata cases; and evaluated the frequency of lineage-level mismatch for the trivalent vaccine. The median proportion of influenza cases caused by influenza B virus was 23.4%, with a tendency (borderline statistical significance, p = 0.060) to be higher in tropical vs. temperate countries. Influenza B was the dominant virus type in about one every seven seasons. In temperate countries, influenza B epidemics occurred on average three weeks later than influenza A epidemics; no consistent pattern emerged in the tropics. The two B lineages caused a comparable proportion of influenza B cases globally, however the B/Yamagata was more frequent in temperate countries, and the B/Victoria in the tropics (p = 0.048). B/Yamagata patients were significantly older than B/Victoria patients in almost all countries. A lineage-level vaccine mismatch was observed in over 40% of seasons in temperate countries and in 30% of seasons in the tropics. The type B virus caused a substantial proportion of influenza infections globally in the 21st century, and its two virus lineages differed in terms of age and geographical distribution of patients. These findings will help inform health policy decisions aiming to reduce disease burden associated with seasonal influenza. |
| Competing Interests: | Clotilde El-Guerche Séblain is an employee of Sanofi Pasteur. She was the coordinator of the research project at Sanofi Pasteur, she helped define the study objectives, and critically revised the manuscript. When reviewing the manuscript, the revisions concerned the epidemiological findings of the study and not the public health findings or conclusions. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Cheryl Cohen has received grant support from Sanofi Pasteur, Advanced Vaccine Initiative, US Centers for Disease Control and Prevention, and payment of travel costs from Parexel. All of the other authors declare that they have no conflict of interests to disclose. |
| References: | Vaccine. 2010 Feb 25;28(9):2149-56. (PMID: 20003926); Pediatr Infect Dis J. 2011 Oct;30(10):833-9. (PMID: 21857263); Virology. 1990 Mar;175(1):59-68. (PMID: 2309452); BMC Public Health. 2012 Nov 15;12:982. (PMID: 23153033); Am J Public Health. 2013 Mar;103(3):e43-51. (PMID: 23327249); PLoS Pathog. 2013 Mar;9(3):e1003194. (PMID: 23505366); BMC Med. 2013 Jun 25;11:153. (PMID: 23800265); J Med Virol. 2013 Nov;85(11):1983-9. (PMID: 23926069); BMJ. 2013 Aug 23;347:f5061. (PMID: 23974637); J Virol. 2014 Jul;88(14):7692-5. (PMID: 24789791); J Clin Virol. 2014 Sep;61(1):156-60. (PMID: 25034374); Clin Infect Dis. 2014 Dec 1;59(11):1519-24. (PMID: 25139969); Elife. 2015 Jan 16;4:e05055. (PMID: 25594904); J Infect Dis. 2015 Dec 1;212(11):1701-10. (PMID: 25943206); Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:3-12. (PMID: 26256290); BMC Infect Dis. 2015 Aug 21;15:357. (PMID: 26289794); Influenza Other Respir Viruses. 2016 Jan;10(1):14-26. (PMID: 26369646); Am J Epidemiol. 2015 Oct 15;182(8):705-13. (PMID: 26400854); Braz J Infect Dis. 2016 Jan-Feb;20(1):81-90. (PMID: 26626166); Medicine (Baltimore). 2015 Dec;94(52):e2399. (PMID: 26717393); Western Pac Surveill Response J. 2015 Nov 11;6(4):17-23. (PMID: 26798557); Influenza Other Respir Viruses. 2016 Jul;10(4):254-67. (PMID: 26842617); Euro Surveill. 2016;21(4):null. (PMID: 26848118); Hum Vaccin Immunother. 2016 Apr 2;12(4):993-1002. (PMID: 26890005); PLoS One. 2016 Mar 31;11(3):e0152310. (PMID: 27031105); Influenza Other Respir Viruses. 2017 Mar;11(2):102-109. (PMID: 27650482); PLoS One. 2016 Nov 9;11(11):e0166107. (PMID: 27829058); PLoS One. 2017 May 25;12(5):e0177655. (PMID: 28542324); Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):249-265. (PMID: 28613092); Euro Surveill. 2017 Aug 31;22(35):null. (PMID: 28877844); Influenza Other Respir Viruses. 2018 May;12(3):383-411. (PMID: 29127742); Vaccine. 2018 Jan 2;36(1):107-113. (PMID: 29174679); Lancet. 2018 Mar 31;391(10127):1285-1300. (PMID: 29248255); Euro Surveill. 2018 Jan;23(1):. (PMID: 29317016); Vaccine. 2018 Feb 8;36(7):997-1007. (PMID: 29373192); Influenza Other Respir Viruses. 2018 Jan;12(1):132-137. (PMID: 29446233); Influenza Other Respir Viruses. 2018 Jan;12(1):3-9. (PMID: 29460425); Euro Surveill. 2018 Mar;23(13):. (PMID: 29616611); Euro Surveill. 2018 Apr;23(16):. (PMID: 29692315); BMC Infect Dis. 2018 Jun 8;18(1):269. (PMID: 29884140) |
| Substance Nomenclature: | 0 (Influenza Vaccines) |
| Entry Date(s): | Date Created: 20190913 Date Completed: 20200306 Latest Revision: 20200306 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6742362 |
| DOI: | 10.1371/journal.pone.0222381 |
| PMID: | 31513690 |
| Database: | MEDLINE |
Historical Article; Journal Article; Research Support, Non-U.S. Gov't